However, in clinical practice, it is not easy for physicians to choose the optimal treatment sequence (upfront surgery vs. neoadjuvant chemotherapy) for HR+HER2- breast cancer with 1–2 suspicious ALNs on radiologic modalities because the actual nodal burden is unknown. This evidence concerns the gene ERBB2 and breast carcinoma.